New technologies position TGen, ASU and Seattle cancer center to
play key roles in international medical efforts
PHOENIX, Ariz. - May 27, 2009 - The Translational Genomics Research
Institute (TGen) has hired a key player in Arizona's efforts to
become a world-premier center for personalized medicine.
Dr. Konstantinos "Kostas" Petritis is the first Head of TGen's new
Center for Proteomics. The new center will play a significant role
in the Partnership for Personalized Medicine (PPM), and in the
PPM's development of specifically targeted treatments for
individual patients afflicted with cancer and other debilitating
conditions.
The PPM is an alliance founded in 2007 between TGen, Arizona State
University's Biodesign Institute and Seattle's Fred Hutchinson
Cancer Research Center.
"Establishment of the Center for Proteomics at TGen is integral to
the success of the Partnership for Personalized Medicine," said Dr.
Lee Hartwell, a 2001 Nobel laureate and Executive Committee
Chairman of PPM.
"The selection of Dr. Petritis adds a completely new capability to
the already extraordinary capacities of TGen to do complex studies
across the spectrum of disease-related biological molecules," said
Dr. Hartwell, President and Director of the Hutchinson
Center.
Proteomics is a branch of molecular biology involving the study of
proteins and how they affect the structure and functions of DNA,
cells, tissues and organisms in the cause and prevention of
disease.
TGen's new Center for Proteomics is an industrial-scale proteomics
biomarker discovery, verification and validation facility. This
cutting-edge laboratory will work with world-recognized experts to
translate our understanding of genomic variation and proteins into
new diagnostics and treatments.
Dr. Petritis most recently was a senior research scientist for a
federal laboratory in Washington that promoted energy independence,
environmental protection and technological innovations.
"Biomarker discovery efforts of the last 10-plus years have, thus
far, failed to produce an FDA-approved biomarker that was
discovered and validated through proteomics. I envision that TGen's
new Center for Proteomics will be able to accomplish this task,"
Dr. Petritis said. "All of the exceptional scientists chosen to be
part of this exciting venture will work together to identify a
research path that will guarantee the success of PPM's
goals."
The naming of Dr. Petritis as Head of the Center for Proteomics
follows the appointment of Dr. Joshua LaBaer as Director of the new
Virginia G. Piper Center for Personalized Diagnostics at ASU's
Biodesign Institute. Dr. LaBaer most recently was Director of the
Harvard Institute of Proteomics.
"Arizona is assembling a powerhouse of talent in proteomics, an
area of science that is allowing us to better identify distinct
molecular variations in diseases, so that we can more quickly
arrive at the right diagnosis and the right treatment for each
individual patient," said Dr. Alan Nelson, Executive Director of
ASU's Biodesign Institute. "We are confident that our collaboration
will have a profound impact on people's health."
Dr. Jeffrey Trent, TGen's President and Research Director, said the
hiring of Dr. Petritis is a milestone in the development of the
PPM.
"We are excited about Dr. Petritis joining our TGen family. His
addition helps complete the building blocks of personnel and
facilities needed to create the Partnership for Personalized
Medicine," Dr. Trent said. "With Dr. Petritis on board, TGen's
Center for Proteomics is poised to make a substantial and positive
difference in the lives of patients with cancer and other
devastating diseases."
TGen's Center for Proteomics initially will focus on the discovery
and validation of biomarkers in support of Luxembourg Project Lung
Cancer, one of three programs TGen has initiated with the nation of
Luxembourg to help turn that country into Europe's premier
biomedical center. The other two projects are: the Integrated
BioBank of Luxembourg, which will create a repository for tissue
samples; and the Center for Systems Biology Luxembourg, which will
track the genetic basis of disease and develop health tests based
on proteins. TGen will provide support, core expertise and training
to enable Luxembourg to establish its genomics and proteomics
capabilities.
The Center for Proteomics - located at TGen's downtown Phoenix
headquarters - also will provide a core resource to support
collaborative proteomics studies within the TGen community. TGen
also has facilities in Scottsdale and Flagstaff, and is pursuing a
major alliance with the Van Andel Research Institute in Grand
Rapids, Mich.
The center's construction is nearly complete. Equipment
installations will begin in June. The center will be operational
this summer.
Dr. Petritis started his career in Analytical Chemistry in the
biotechnology department of VIORYL Inc., a chemical and
agricultural firm based near Athens, Greece. Dr. Petritis received
his Doctorate and Master's degrees in Analytical Chemistry from
France's University of Orleans.
Most recently, Dr. Petritis worked as a senior research scientist
at the Pacific Northwest National Laboratory in Richland, Wash.,
specifically in the Biological Separations and Mass
Spectrometry/Proteomics group at PNNL's Environmental Molecular
Sciences Laboratory, a branch of the Office of Science of the U.S.
Department of Energy.
Dr. Petritis' areas of expertise include proteomics, metabolomics
and the development of mass spectrometry-based analytical methods
for the analysis of biomolecules from a variety of sample types,
including agricultural and biological fluids. In addition, he has
worked on methods that significantly accelerate
biospecimen/biofluid sample preparation, which is a current
bottleneck in proteomics. Dr. Petritis has played an integral role
in developing tools that increase the confidence of proteomic
identifications through auxiliary metrics, integrating top-down and
bottom-up proteomics, and developing new ways for performing
proteomic measurements.
*
About TGen
The Translational Genomics Research Institute (TGen) is a
non-profit organization dedicated to conducting groundbreaking
research with life changing results. Research at TGen is focused on
helping patients with diseases such as cancer, neurological
disorders and diabetes. TGen is on the cutting edge of
translational research where investigators are able to unravel the
genetic components of common and complex diseases. Working with
collaborators in the scientific and medical communities, TGen
believes it can make a substantial contribution to the efficiency
and effectiveness of the translational process. For more
information, visit: www.tgen.org.
Press Contact:
Steve Yozwiak
TGen Senior Science Writer
602-343-8704
[email protected]
*
About the Biodesign Institute
The Biodesign Institute at Arizona State University pursues
research to create personalized medical diagnostics and treatments,
outpace infectious disease, clean the environment, develop
alternative energy sources, and secure a safer world. Using a team
approach that fuses the biosciences with nanoscale engineering and
advanced computing, the Biodesign Institute collaborates with
academic, industrial and governmental organizations globally to
accelerate these discoveries to market. For more information, go
to: www.biodesign.asu.edu.
Press Contact:
Joe Caspermeyer
Media Relations Manager
Biodesign Institute
480-727-0369
[email protected]
*
About Fred Hutchinson Cancer Research Center
At Fred Hutchinson Cancer Research Center, our interdisciplinary
teams of world-renowned scientists and humanitarians work together
to prevent, diagnose and treat cancer, HIV/AIDS and other diseases.
Our researchers, including three Nobel laureates, bring a
relentless pursuit and passion for health, knowledge and hope to
their work and to the world. For more information, please visit
www.fhcrc.org.
Press Contact:
Dean Forbes
Media Relations Manager
206-667-2896
[email protected]
# # #